JP2025506783A - グサシチニブの固体形態 - Google Patents

グサシチニブの固体形態 Download PDF

Info

Publication number
JP2025506783A
JP2025506783A JP2024549676A JP2024549676A JP2025506783A JP 2025506783 A JP2025506783 A JP 2025506783A JP 2024549676 A JP2024549676 A JP 2024549676A JP 2024549676 A JP2024549676 A JP 2024549676A JP 2025506783 A JP2025506783 A JP 2025506783A
Authority
JP
Japan
Prior art keywords
gusacitinib
crystalline
peaks
hcl salt
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024549676A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025506783A5 (https=
Inventor
ラジモハン ムスサミー アナンサ
シン アミット
シン チャンチャル
レンガラジ プラサプ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceuticals International GmbH
Original Assignee
Teva Pharmaceuticals International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceuticals International GmbH filed Critical Teva Pharmaceuticals International GmbH
Publication of JP2025506783A publication Critical patent/JP2025506783A/ja
Publication of JP2025506783A5 publication Critical patent/JP2025506783A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024549676A 2022-02-23 2023-02-23 グサシチニブの固体形態 Pending JP2025506783A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
IN202211009506 2022-02-23
IN202211009506 2022-02-23
IN202211028117 2022-05-16
IN202211028117 2022-05-16
IN202211031922 2022-06-03
IN202211031922 2022-06-03
IN202211053997 2022-09-21
IN202211053997 2022-09-21
IN202311006675 2023-02-02
IN202311006675 2023-02-02
IN202311007408 2023-02-06
IN202311007408 2023-02-06
PCT/US2023/013668 WO2023164024A1 (en) 2022-02-23 2023-02-23 Solid state forms of gusacitinib

Publications (2)

Publication Number Publication Date
JP2025506783A true JP2025506783A (ja) 2025-03-13
JP2025506783A5 JP2025506783A5 (https=) 2025-11-04

Family

ID=85640884

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024549676A Pending JP2025506783A (ja) 2022-02-23 2023-02-23 グサシチニブの固体形態

Country Status (6)

Country Link
US (1) US20250171448A1 (https=)
EP (1) EP4482836A1 (https=)
JP (1) JP2025506783A (https=)
KR (1) KR20240151808A (https=)
CA (1) CA3244694A1 (https=)
WO (1) WO2023164024A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202510870A (zh) * 2023-07-27 2025-03-16 美商自由生物有限公司 Jak/syk抑制劑之組合物及固體形式
WO2025020171A1 (en) * 2023-07-27 2025-01-30 Libertas Bio, Inc. Crystalline forms of a jak/syk inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2748166T3 (pl) * 2011-08-23 2019-05-31 Asana Biosciences Llc Związki pirimido-pirydazynonowe oraz ich zastosowanie
WO2018187294A1 (en) * 2017-04-03 2018-10-11 Asana Biosciences, Llc Pyrimido-pyridazinone compound combinations, methods, kits and formulations thereof
EP3875078A1 (en) * 2020-03-06 2021-09-08 Dompe' Farmaceutici S.P.A. Compounds for the treatment of covid-19

Also Published As

Publication number Publication date
WO2023164024A1 (en) 2023-08-31
KR20240151808A (ko) 2024-10-18
EP4482836A1 (en) 2025-01-01
US20250171448A1 (en) 2025-05-29
CA3244694A1 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
US12509456B2 (en) Solid state forms of ripretinib
JP2025113269A (ja) ベルモスジル及びベルモスジル塩の固体形態
US20240199578A1 (en) Solid state forms of zavegepant and process for preparation thereof
JP2025506783A (ja) グサシチニブの固体形態
US20230097240A1 (en) Solid state forms of asciminib and processes for the preparation thereof
US11427533B2 (en) Crystalline polymorphs of bardoxolone methyl
EP4271678A1 (en) Solid state forms of capivasertib and process for preparation thereof
JP2025536064A (ja) ザベゲパント塩酸塩の固体形態及びその調製方法
WO2021216628A1 (en) Solid state forms of trifarotene and process for preparation thereof
WO2021183709A1 (en) Solid state forms of avapritinib and process for preparation thereof
EP4051659B1 (en) Solid state forms of fezagepras and process for preparation thereof
US20240294537A1 (en) SOLID STATE FORMS OF 4-[[4-(4-CHLOROANILINO)FURO[2,3-d]PYRIDAZIN-7-yl]OXYMETHYL]-N-METHYLPYRIDINE-2-CARBOXAMIDE AND SALT THEREOF
US20240279167A1 (en) Crystalline polymorphs of rigosertib sodium
CN118974054A (zh) 古沙替尼的固态形式
JP2026501777A (ja) ブリラロキサジンの固体形態及びブリラロキサジン塩
JP2026506400A (ja) デルゴシチニブの固体形態及びその方法
US20230357163A1 (en) Solid state forms of gefapixant and process for preparation thereof
US20230373998A1 (en) Solid state forms of lorecivivint
EP4665732A1 (en) Salts and solid forms of elenestinib
WO2024180476A1 (en) Solid state forms of anlotinib and process for preparation thereof
WO2025257758A1 (en) Solid state forms of navacaprant
WO2026003809A1 (en) Solid state forms of iptacopan hydrochloride
EP4594313A1 (en) Solid state forms of denifanstat
WO2022256215A1 (en) Solid state form of centanafadine hcl and process for preparation thereof
EP3999514A1 (en) Crystalline lorlatinib : fumaric acid and solid state form thereof

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20250812

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250812

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251024

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251024